The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer

ER-targeted therapeutics provide valuable treatment options for patients with ER+ breast cancer, however, current relapse and mortality rates emphasize the need for improved therapeutic strategies. The recent discovery of prevalent ESR1 mutations in relapsed tumors underscores a sustained reliance o...

Descripció completa

Dades bibliogràfiques

Autors principals:	James D Joseph, Beatrice Darimont, Wei Zhou, Alfonso Arrazate, Amy Young, Ellen Ingalla, Kimberly Walter, Robert A Blake, Jim Nonomiya, Zhengyu Guan, Lorna Kategaya, Steven P Govek, Andiliy G Lai, Mehmet Kahraman, Dan Brigham, John Sensintaffar, Nhin Lu, Gang Shao, Jing Qian, Kate Grillot, Michael Moon, Rene Prudente, Eric Bischoff, Kyoung-Jin Lee, Celine Bonnefous, Karensa L Douglas, Jackaline D Julien, Johnny Y Nagasawa, Anna Aparicio, Josh Kaufman, Benjamin Haley, Jennifer M Giltnane, Ingrid E Wertz, Mark R Lackner, Michelle A Nannini, Deepak Sampath, Luis Schwarz, Henry Charles Manning, Mohammed Noor Tantawy, Carlos L Arteaga, Richard A Heyman, Peter J Rix, Lori Friedman, Nicholas D Smith, Ciara Metcalfe, Jeffrey H Hager
Format:	Artigo
Idioma:	Inglês
Publicat:	eLife Sciences Publications Ltd 2016-07-01
Col·lecció:	eLife
Matèries:	breast cancer estrogen receptor SERD GDC-0810
Accés en línia:	https://elifesciences.org/articles/15828
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!